Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Pancreatic Neuroendocrine Tumors
Last updated October 11, 2013
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Thromboembolic events prevention, (atrial fibrillation)
Last updated October 10, 2013
Status:
Concluded with an LOI
Manufacturer:
Shire Pharma Canada ULC
Indication:
Fabry Disease
Last updated September 24, 2013
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
Metastatic Castration-Resistant Prostate Cancer
Last updated September 23, 2013
Status:
Concluded with an LOI
Manufacturer:
Sanofi Genzyme Canada
Indication:
Fabry Disease
Last updated September 20, 2013
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Myelofibrosis
Last updated September 3, 2013
Status:
Negotiations were not pursued
Manufacturer:
Allergan Inc.
Indication:
Hypertension
Last updated August 22, 2013
Aloxi IV (palonosetron hydrochloride)
Status:
Negotiations were not pursued
Manufacturer:
Eisai Limited
Indication:
Nausea and vomiting (chemotherapy induced) prevention
Last updated August 21, 2013
Aloxi (palonosetron hydrochloride)
Status:
Negotiations were not pursued
Manufacturer:
Eisai Limited
Indication:
Nausea and vomiting (chemotherapy induced) prevention
Last updated August 21, 2013
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Pancreatic Neuroendocrine Tumors
Last updated August 14, 2013